Resources
18 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 6/22/2023 (updated 3/28/2024)
The Buncombe Bridge to Care (BB2C): Post-Overdose Buprenorphine Field Initiation Program Toolkit was developed by Buncombe County Emergency Services Community Paramedicine and UNC Health Sciences at Mountain Area Health Education Center (MAHEC). This toolkit describes the project and protocols utilized. It is not intended to be a comprehensive guide or manual, but instead to inspire communities to increase access to lifesaving medication for the marginalized community of people who use drugs.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Patients Treated With Buprenorphine in Emergency Departments More Likely To Continue After Discharge
Posted 4/11/2023 (updated 3/27/2024)
In this cohort study of 17,428 Medicaid-enrolled adults with an emergency department encounter for opioid use disorder, the buprenorphine treatment Opioid Hospital Quality Improvement Program (O-HQIP) pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
Posted 4/5/2023 (updated 3/27/2024)
The Northwest Prevention Technology Transfer Center (PTTC) Network has developed an Alcohol Awareness Toolkit to use during Alcohol Awareness Month. The Alcohol Awareness Toolkit will help you raise awareness about alcohol-related harms and the importance of strong alcohol policies. It also encourages engagement from prevention and public health stakeholders to strategically educate and inform decision-makers about effective alcohol policies by providing easy-to-personalize, templated opinion editorials, letters to legislators, and proclamations.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.